Tisotumab vedotin was the first-in-class MMAE-conjugated anti-TF monoclonal antibody licensed in the US (2021) and Europe (2024) as a second- or third-line treatment for recurrent cervical cancer. This evidence concerns the gene TF and cervical carcinoma.